<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02567695</url>
  </required_header>
  <id_info>
    <org_study_id>GBT440-004</org_study_id>
    <nct_id>NCT02567695</nct_id>
  </id_info>
  <brief_title>A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Single-Dose, Open-Label, Randomized, Two-Period Crossover Study to Evaluate the Relative Bioavailability of GBT440 300 mg Administered as Capsule Formulations in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Blood Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Blood Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the relative bioavailability of a single 300 mg dose
      of GBT440 administered as a high strength (1 × 300 mg) capsule versus a low strength (3 × 100
      mg) capsule formulation in healthy fasted subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum observed concentration (Cmax) of GBT440 in whole blood</measure>
    <time_frame>predose, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose, and Day 12, Day 20, and Day 28 for each period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area under the concentration-time curve (AUC) from time 0 to the time of the last quantifiable concentration (AUCt) of GBT440 in whole blood</measure>
    <time_frame>predose, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose, and Day 12, Day 20, and Day 28 for each period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): AUC from time 0 extrapolated to infinity (AUCinf) of GBT440 in whole blood</measure>
    <time_frame>predose, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose, and Day 12, Day 20, and Day 28 for each period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): The time that Cmax was observed (tmax) of GBT440 in whole blood</measure>
    <time_frame>predose, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose, and Day 12, Day 20, and Day 28 for each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Terminal elimination half-life (t½) of GBT440 in whole blood</measure>
    <time_frame>predose, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose, and Day 12, Day 20, and Day 28 for each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Apparent oral clearance (CL/F) of GBT440 in whole blood</measure>
    <time_frame>predose, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose, and Day 12, Day 20, and Day 28 for each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Apparent volume of distribution during the terminal phase (Vz/F) of GBT440 in whole blood</measure>
    <time_frame>predose, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose, and Day 12, Day 20, and Day 28 for each period</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Treatment-emergent adverse events (TEAEs) and serious adverse events</measure>
    <time_frame>Baseline to Period 2 Day 28</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical laboratory results</measure>
    <time_frame>Baseline to Period 2 Day 28</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in physical examination findings</measure>
    <time_frame>Baseline to Period 2 Day 28</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in vital signs</measure>
    <time_frame>Baseline to Period 2 Day 28</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in electrocardiograms (ECGs)</measure>
    <time_frame>Baseline to Period 2 Day 28</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A with one 300 mg capsule (high-strength) of GBT440 administered in a fasted state (test) in dosing Period 1 followed by Treatment B with 300 mg (3 × 100 mg) capsules (low-strength) of GBT440 administered in a fasted state (reference) in dosing Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment B with 300 mg (3 × 100 mg) capsules (low-strength) of GBT440 administered in a fasted state (reference) in dosing Period 1 followed by Treatment A with one 300 mg capsule (high-strength) of GBT440 administered in a fasted state (test) in dosing Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GBT440</intervention_name>
    <description>Test: GBT440 300 mg capsule (high-strength) Reference: GBT440 100 mg capsule (low-strength)</description>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is a female of non-childbearing potential or male, who is healthy, nonsmoking,
             and 18 to 60 years old, inclusive, at screening

          -  Male subjects agree to use contraception

          -  Willing and able to give written informed consent

        Exclusion Criteria:

          -  Evidence or history of clinically significant metabolic, allergic, dermatological,
             hepatic, renal,hematological, pulmonary, cardiovascular, gastrointestinal,
             neurological, or psychiatric disorder

          -  History of hypersensitivity or allergy to drugs, foods, or other substances

          -  History or presence of abnormal electrocardiogram or hypertension

          -  History of alcohol abuse, illicit drug use, significant mental illness, physical
             dependence to any opioid, or any history of drug abuse or addiction within 1 year of
             screening

          -  Participated in another clinical trial of an investigational drug within 30 days (or 5
             half-lives of the investigational drug, whichever is longer) prior to Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carla Washington, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Global Blood Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICON Early Phase Services, LLC Clinical Research Unit</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2015</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

